
NICE recommends avatrombopag to treat thrombocytopenia in chronic liver disease
pharmafile | March 4, 2020 | News story | Research and Development |Â Â Avatrombopag, NHS, NICE, UK, chronic liver diseaseÂ
UK drug watchdog NICE has announced its final draft guidance recommending avatrombopag for routine use on the NHS in England and Wales for the treatment of thrombocytopenia in chronic liver disease patients who require surgery.
Avatrombopag has been shown to elevate platelet levels for longer periods than platelet transfusions. The recommendation provides patients with a new treatment option which can be self-administered at home, reducing the time they will need to spend in hospital.
The therapy has two list prices: for a five-day course of treatment, it costs £640 for patients with between 40,000 and 50,000 platelets per microlitre of blood, and £960 for those with less than 40,000 per microlitre.
It is estimated that around 10% of patients with chronic liver disease will need surgery in in their final two years of life.
Thrombocytopenia, or low platelet count, is the most common haematological abnormality in liver disease, which itself is on track to become the biggest cause of death in patients under the age of 65, with around 62,000 deaths a year in this age group.
Matt Fellows
Related Content

NHS spends £240m storing patient records as digital reforms gather pace
The NHS spent almost £240m storing patient records in 2024/25, according to analysis by The …

NHS awards national diabetes education contract to Leicester programme
University Hospitals of Leicester NHS Trust (UHL) has been awarded a five-year contract to deliver …

Product value to pathway impact: What the CVD Modern Service Framework means for pharma
By Sabina Syed and Ewan Maule The Cardiovascular Disease Modern Service Framework1(CVD MSF) begins with a …




